Qiagen to Buy eGene in $34M Cash and Stock Deal | GenomeWeb
NEW YORK (GenomeWeb News) - Qiagen said today it will buy the sample-separation technology company eGene in a cash and stock deal valued at around $34 million.
 
Qiagen offered $.65 cash and .0416 of its common shares for each share of eGene’s stock.
 
eGene, which is based in Irvine, Calif., sells the HAD-GT12 Genetic Analyzer, a multi-channel sample separation and analysis solution that includes software and a range of consumable cartridges.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.